Difference between revisions of "Acinic cell carcinoma"

Jump to navigation Jump to search

Acinic cell carcinoma (view source)

Revision as of 16:54, 27 October 2021

3 bytes added ,  16:54, 27 October 2021
→‎Grading
 
(2 intermediate revisions by the same user not shown)
Line 98: Line 98:
*Nuclear atypia.
*Nuclear atypia.
*[[Perineural invasion]].
*[[Perineural invasion]].
*[[Mitoses]].
*Mitoses.
*Infiltrative margin.
*Infiltrative margin.
*Tumour sclerosis.
*Tumour sclerosis.
Line 112: Line 112:


==IHC==
==IHC==
*CK7 +ve.<ref name=pmid26166029>{{cite journal |vauthors=Li X, Shi Z, Wang Y, Liu Y, Liu T |title=Immunohistochemical expression of cytokeratins in human salivary gland acinic cell carcinomas |journal=Oral Surg Oral Med Oral Pathol Oral Radiol |volume=120 |issue=2 |pages=248–57 |date=August 2015 |pmid=26166029 |doi=10.1016/j.oooo.2015.04.014 |url=}}</ref>
*CK7 +ve.<ref name=pmid26166029>{{cite journal |authors=Li X, Shi Z, Wang Y, Liu Y, Liu T |title=Immunohistochemical expression of cytokeratins in human salivary gland acinic cell carcinomas |journal=Oral Surg Oral Med Oral Pathol Oral Radiol |volume=120 |issue=2 |pages=248–57 |date=August 2015 |pmid=26166029 |doi=10.1016/j.oooo.2015.04.014 |url=}}</ref>
*CK19 +ve.<ref name=pmid26166029/>
*CK19 +ve.<ref name=pmid26166029/>
*NR4A3 +ve (nuclear) (5 of 6 cases<ref name=pmid33959239>{{cite journal |vauthors=Owosho A, Tyler D, Adesina O, Odujoko O, Summersgill K |title=NR4A3 (NOR-1) Immunostaining Shows Better Performance than DOG1 Immunostaining in Acinic Cell Carcinoma of Salivary Gland: a Preliminary Study |journal=J Oral Maxillofac Res |volume=12 |issue=1 |pages=e4 |date=2021 |pmid=33959239 |pmc=8085676 |doi=10.5037/jomr.2021.12104 |url=}}</ref>; 18 of 20 cell blocks<ref name=pmid26166029>{{cite journal |vauthors=Li X, Shi Z, Wang Y, Liu Y, Liu T |title=Immunohistochemical expression of cytokeratins in human salivary gland acinic cell carcinomas |journal=Oral Surg Oral Med Oral Pathol Oral Radiol |volume=120 |issue=2 |pages=248–57 |date=August 2015 |pmid=26166029 |doi=10.1016/j.oooo.2015.04.014 |url=}}</ref>; 9 of 9 surgicals<ref name=pmid26166029/>).
*NR4A3 +ve (nuclear) (5 of 6 cases<ref name=pmid33959239>{{cite journal |authors=Owosho A, Tyler D, Adesina O, Odujoko O, Summersgill K |title=NR4A3 (NOR-1) Immunostaining Shows Better Performance than DOG1 Immunostaining in Acinic Cell Carcinoma of Salivary Gland: a Preliminary Study |journal=J Oral Maxillofac Res |volume=12 |issue=1 |pages=e4 |date=2021 |pmid=33959239 |pmc=8085676 |doi=10.5037/jomr.2021.12104 |url=}}</ref>; 18 of 20 cell blocks<ref name=pmid26166029>{{cite journal |authors=Li X, Shi Z, Wang Y, Liu Y, Liu T |title=Immunohistochemical expression of cytokeratins in human salivary gland acinic cell carcinomas |journal=Oral Surg Oral Med Oral Pathol Oral Radiol |volume=120 |issue=2 |pages=248–57 |date=August 2015 |pmid=26166029 |doi=10.1016/j.oooo.2015.04.014 |url=}}</ref>; 9 of 9 surgicals<ref name=pmid26166029/>).
*Alpha1-ACT (also ''AACT'') +ve.
*Alpha1-ACT (also ''AACT'') +ve.


Line 125: Line 125:


==Molecular==
==Molecular==
*t(4;9)(q13;q31).<ref name=pmid33959239>{{cite journal |vauthors=Owosho A, Tyler D, Adesina O, Odujoko O, Summersgill K |title=NR4A3 (NOR-1) Immunostaining Shows Better Performance than DOG1 Immunostaining in Acinic Cell Carcinoma of Salivary Gland: a Preliminary Study |journal=J Oral Maxillofac Res |volume=12 |issue=1 |pages=e4 |date=2021 |pmid=33959239 |pmc=8085676 |doi=10.5037/jomr.2021.12104 |url=}}</ref>  
*t(4;9)(q13;q31).<ref name=pmid33959239>{{cite journal |authors=Owosho A, Tyler D, Adesina O, Odujoko O, Summersgill K |title=NR4A3 (NOR-1) Immunostaining Shows Better Performance than DOG1 Immunostaining in Acinic Cell Carcinoma of Salivary Gland: a Preliminary Study |journal=J Oral Maxillofac Res |volume=12 |issue=1 |pages=e4 |date=2021 |pmid=33959239 |pmc=8085676 |doi=10.5037/jomr.2021.12104 |url=}}</ref>  
**''Secretory Ca-binding phosphoprotein'' (SCPP) at 4q13.<ref name=pmid30664630>{{cite journal |vauthors=Haller F, Bieg M, Will R, Körner C, Weichenhan D, Bott A, Ishaque N, Lutsik P, Moskalev EA, Mueller SK, Bähr M, Woerner A, Kaiser B, Scherl C, Haderlein M, Kleinheinz K, Fietkau R, Iro H, Eils R, Hartmann A, Plass C, Wiemann S, Agaimy A |title=Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands |journal=Nat Commun |volume=10 |issue=1 |pages=368 |date=January 2019 |pmid=30664630 |pmc=6341107 |doi=10.1038/s41467-018-08069-x |url=}}</ref>
**''Secretory Ca-binding phosphoprotein'' (SCPP) at 4q13.<ref name=pmid30664630>{{cite journal |authors=Haller F, Bieg M, Will R, Körner C, Weichenhan D, Bott A, Ishaque N, Lutsik P, Moskalev EA, Mueller SK, Bähr M, Woerner A, Kaiser B, Scherl C, Haderlein M, Kleinheinz K, Fietkau R, Iro H, Eils R, Hartmann A, Plass C, Wiemann S, Agaimy A |title=Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands |journal=Nat Commun |volume=10 |issue=1 |pages=368 |date=January 2019 |pmid=30664630 |pmc=6341107 |doi=10.1038/s41467-018-08069-x |url=}}</ref>
**''Nuclear Receptor Subfamily 4 Group A Member 3'' (NR4A3) at 9q31.<ref name=pmid30664630/>
**''Nuclear Receptor Subfamily 4 Group A Member 3'' (NR4A3) at 9q31.<ref name=pmid30664630/>


Line 143: Line 143:


Comment:
Comment:
Immunostains are in keeping with acinic cell carcinoma (mammaglobin, S-100 and p63 are all NEGATIVE). A PAS stain is positive in the tumour.
The tumour stains as follows:
POSITIVE: CK7, CK19, AACT, PAS.
NEGATIVE: mammaglobin, S-100, p63.
 
The staining is in keeping with acinic cell carcinoma.
</pre>
</pre>


Michael
49,012

edits

Retrieved from "https://librepathology.org/wiki/Special:MobileDiff/51575...51581"

Navigation menu